Newsroom

Explore ViewRay events, images & videos, press releases, and the most up-to-date coverage of MRIdian.

ViewRay In The News

ViewRay® to Participate in Upcoming Investor Conferences

ViewRay, Inc. (NASDAQ: VRAY) today announced that the Company will participate in three upcoming virtual investor conferences.  

Cantor Virtual Global Healthcare Conference

Wednesday, September 16, 2020

Virtual 1x1 Meetings

Morgan Stanley 18th Annual Global Healthcare Conference

Friday, September 18, 2020   |  11:00 AM ET

Virtual Fireside Chat & 1x1 Meetings

http://investors.viewray.com/events-and-presentations/upcoming-events

 

Oppenheimer Fall Healthcare Life Sciences & MedTech Summit

Wednesday, September 23, 2020 | 2:30 pm ET

Virtual Fireside Chat & 1x1 Meetings

https://wsw.com/webcast/oppenheimer5/vray/2755458

 
A replay of the fireside chats will be available for 14 days after the date of the presentation at http://investors.viewray.com/events-and-presentations/upcoming-events.

September 4, 2020

10,000th Patient Receives Treatment with ViewRay’s MRIdian System

ViewRay, Inc. (Nasdaq: VRAY) announced today that 10,000 patients have been treated to date using the company's MRIdian® MRI-Guided Radiation Therapy System, the world's first system to combine MR imaging with radiation delivery. Unlike conventional radiation therapy systems, MRIdian combines an MRI system with a radiation therapy system. This feature, together with other technical innovations, offers advantages for the delivery of safe and effective radiotherapy. These features include the ability to see the tumor and surrounding tissue during treatment, adaptation of the therapy in response to changes in patient anatomy and tumor size between treatments, continuously track the tumor during treatment, and automatically pause the radiation if the tumor moves outside of the boundary. As a result, the system is able to deliver high-dose radiation to the tumor while protecting the surrounding healthy tissue from damage.

September 1, 2020

ViewRay, GenesisCare and the University of Oxford Announce Groundbreaking Compassionate Access Programme Now Open to UK Patients with Localized Pancreatic Cancer

ViewRay, Inc. (Nasdaq: VRAY) announced today that the GenesisCare Foundation's Compassionate Access Programme is now accepting patients for treatment on the MRIdian® MRI-Guided Radiation Therapy System. The program, in collaboration with the University of Oxford, is available to eligible National Health Service (NHS) patients with localized pancreatic cancer and is designed to improve access to precision radiotherapy in the United Kingdom, where patients have variable access to this innovative treatment. This is particularly relevant for patients as the COVID-19 pandemic has reduced the availability and safety of surgery and chemotherapy.

August 27, 2020

Dartmouth-Hitchcock Health Begins Patient Treatments with ViewRay’s MRIdian Linac

ViewRay, Inc. (Nasdaq: VRAY) announced today that Dartmouth-Hitchcock Health in New Hampshire has begun patient treatments with the MRIdian® MRI-Guided Therapy System, a cutting-edge radiation therapy device that combines the latest innovations in precision radiation delivery and ground-breaking MR-guidance. Dartmouth-Hitchcock Health is a non-profit academic health system primarily serving New Hampshire and Vermont as well as patients from across New England. As the largest health care system and employer in New Hampshire, Dartmouth-Hitchcock Health is committed to providing the highest quality of care to the nearly two million community members it serves. The addition of MRIdian brings cutting-edge MRI-guided radiation therapy closer to home for patients throughout the region and opens entirely new opportunities for research and clinical applications.

August 13, 2020

Kaohsiung Medical University Chung-Ho Memorial Hospital Begins Patient Treatments with ViewRay’s MRIdian Linac

ViewRay, Inc. announced today that Kaohsiung Medical University Chung-Ho Memorial Hospital (KMUH) in Kaohsiung City, Taiwan has begun patient treatments with the MRIdian® MR-Guided Radiation Therapy System, a cutting-edge device that delivers personalized cancer care by combining the latest innovations in precision radiation delivery with ground-breaking MR-guidance. The first two patients treated at KMUH on MRIdian were provided care for prostate cancer and tumor lesions in the left lung. Both treatments took advantage of MRIdian's automated beam-gating technology, protecting surrounding organs at risk.

August 5, 2020

ViewRay Reports Second Quarter 2020 Results

ViewRay, Inc. (Nasdaq: VRAY) today announced financial results for the second quarter ended June 30, 2020.

Second Quarter 2020 Highlights:
  • Total revenue of $14.2 million, primarily from two revenue units, compared to $30.2 million, primarily from five revenue units, in the second quarter of 2019.
  • Received four new orders for MRIdian systems totaling $24.6 million, compared to three new orders totaling $18.1 million in the second quarter of 2019.
  • Total backlog was $232.2 million as of June 30, 2020, compared to $219.3 million as of June 30, 2019.
  • Cash and cash equivalents were $179.5 million as of June 30, 2020.
  • Announced workforce reductions of approximately 20% as well as a program designed to temporarily retain select senior leaders, including Shar Matin, while also providing an option for them to continue with the Company if certain business and financial targets are achieved.

July 30, 2020

ViewRay Announces Conference Call for Second Quarter 2020 Financial Results to be Held After Market on July 30, 2020

ViewRay will hold a conference call to discuss results on Thursday, July 30, 2020 at 4:30 p.m. ET / 1:30 p.m. PT. The dial-in numbers are (844) 277-1426 for domestic callers and (336) 525-7129 for international callers. The conference ID number is 4968496. A live webcast of the conference call will be available on the investor relations page of ViewRay's corporate website at www.investors.viewray.com.

July 13, 2020

ViewRay Announces 1-Year Outcomes on MR-Guided Radiation Treatment for Prostate Cancer Without Implanted Markers

ViewRay, Inc. (Nasdaq: VRAY) announced today the publication by the European Urology Oncology Journal of a prospective phase II study of MR-guided radiation therapy (MRgRT) in patients with localized prostate cancer. The publication is a follow-up to early outcomes published in 2019 which reported low incidence of acute toxicity in both clinician- and patient-reported outcomes. The one-year data reported continued absence of grade 3 or higher toxicities and reductions in long-term patient-reported outcome measures after MRIdian treatment. Researchers from Amsterdam University Medical Centers enrolled 101 patients and the study is one of the first to research SBRT in a mix of intermediate- and high-risk prostate cancer patients, a population that is challenging to treat. The journal is the official scientific journal of the European Association of Urology.

June 23, 2020

Boston Globe COVID-19 Article Featuring MRIdian

Brigham’s radiation oncology unit has actually ramped up volume, seeing about 50 percent more patients than usual, to get through its backlog of cancer treatments.

 

“Cancer doesn’t wait,” said Dr. Daniel Cagney, a radiation oncologist. “Initially in March and April, there were significant unknowns, but we’ve been living with this for a few months. ... I feel very confident that we will provide the best care for patients and it’s safe for them to come into the hospital.”

June 15, 2020

ViewRay® to Present at the Jefferies 2020 Virtual Healthcare Conference

ViewRay, Inc. announced today that the Company will present at the Jefferies 2020 Virtual Healthcare Conference. Scott Drake, President and CEO, will participate in a fireside chat at 2:30 p.m. Eastern Time on Tuesday, June 2, 2020.

An audio webcast of the Company's presentation will be available on the investor relations section of ViewRay's website at http://investors.viewray.com/events-and-presentations/upcoming-events. A replay of the webcast will be available for 7 days after the date of the presentation.

May 28, 2020

Providence Portland Medical Center Begins Patient Treatments with ViewRay’s MRIdian Linac

ViewRay, Inc. announced today that Providence Portland Medical Center in Portland, Oregon has begun patient treatments with the MRIdian® MR-Guided Therapy System, a cutting-edge radiation therapy system that combines the latest innovations in precision radiation delivery and ground-breaking MR-guidance.

The MRIdian system at Providence Portland Medical Center is part of The Elsie Franz Finley Radiation Oncology Center and Providence Cancer Institute. MRIdian utilizes on-table soft tissue imaging to allow oncologists to visualize, adapt and target using diagnostic-quality anatomical detail that is unavailable with conventional image-guided radiation therapy (IGRT) technologies.

Areas of particular interest to the Providence Portland Medical Center are the treatment of non-metastatic pancreatic, liver, and prostate cancer using MRIdian, given the system's real-time MR-guidance and on-table adaptive capabilities.

"This technology allows us to track the movements and monitor changes in shape of the target and surrounding organs so that we can modify the radiation beams to fit the picture of the moment, not yesterday's. It permits stronger, shorter, more effective treatments to be delivered with potentially fewer complications," according to Dr. Steven Seung, Medical Director for Radiation Oncology and Gamma Knife Center of Oregon, and a physician at The Oregon Clinic.

May 27, 2020

ViewRay Reports First Quarter 2020 Results

ViewRay, Inc. (Nasdaq: VRAY) today announced financial results for the first quarter ended March 31, 2020. A replay of the webcast will remain available online on the investor relations page of ViewRay's corporate website, www.viewray.com, for 14 days following the call.   First Quarter 2020 Highlights:

  • Total revenue of $14.3 million, primarily from three revenue units including one system upgrade, compared to $20.3 million, primarily from four revenue units including one system upgrade, in the first quarter of 2019.
  • Received four new orders for MRIdian systems totaling $22.6 million, compared to seven new orders totaling $42.8 million in the first quarter of 2019.
  • Total backlog was $230.8 million as of March 31, 2020, compared to $237.5 million as of March 31, 2019.
  • Cash and cash equivalents were $190.2 million as of March 31, 2020.
  • The Company is withdrawing its 2020 guidance, provided on March 12, 2020, as the full impact of COVID-19 remains unknown.
  • The Company announced Zach Stassen as Chief Financial Officer.

April 30, 2020

ViewRay Names Zach Stassen as Chief Financial Officer

ViewRay, Inc. (Nasdaq: VRAY) announced today that Zach Stassen has been named Chief Financial Officer, effective May 18, 2020. Mr. Stassen will report directly to Scott Drake, President and Chief Executive Officer. Mr. Stassen has over 20 years of experience in the medical device and healthcare industry. Most recently he served as Chief Financial Officer and Chief Operating Officer for Bolder Surgical, an innovative, privately held company that develops and markets laparoscopic surgical devices. Prior to Bolder Surgical, he held various finance and business development roles at Spectranetics, including Vice President of Finance, before its acquisition by Royal Philips. Previously, Mr. Stassen was Co-founder and Chief Financial Officer at Emerge Medical, a device company focused on generic orthopedic trauma products, which was acquired by Cardinal Health. He also spent time with the Piper Sandler (formerly Piper Jaffray) medical technology investment banking group. Mr. Stassen earned a master's degree in business administration from the Kellogg School of Management at Northwestern University, and a bachelor's degree from Drake University.

April 30, 2020

ViewRay Announces Appointment of B. Kristine Johnson to its Board of Directors

ViewRay, Inc. (Nasdaq: VRAY) announced the appointment of B. Kristine Johnson to its Board of Directors effective April 14, 2020. Ms. Johnson brings a wealth of health care and medical technology knowledge, as well as broad experience in finance and corporate governance. She is currently President and General Manager of Affinity Capital Management, a venture capital firm that invests primarily in seed and early-stage health care companies in the United States, a position she has held since 2000. Ms. Johnson also currently serves on the Board of Directors for AtriCure and ClearPoint Neuro, Inc., both medical technology companies.

April 16, 2020

ViewRay Announces Conference Call for First Quarter 2020 Financial Results to be Held After Market on April 30, 2020

CLEVELANDApril 9, 2020  ViewRay, Inc. announced today details relating to the release of its first quarter 2020 financial results. ViewRay will hold a conference call to discuss results on Thursday, April 30, 2020 at 4:30 p.m. ET / 1:30 p.m. PT. The dial-in numbers are (844) 277-1426 for domestic callers and (336) 525-7129 for international callers. The conference ID number is 8982097. A live webcast of the conference call will be available on the investor relations page of ViewRay's corporate website at investors.viewray.com. After the live webcast, a replay will remain available online on the investor relations page of ViewRay's corporate website, investors.viewray.com, for 14 days following the call. In addition, a telephonic replay of the call will be available until May 7, 2020. The replay dial-in numbers are (855) 859-2056 for domestic callers and (404) 537-3406 for international callers. Please use the conference ID number 8982097.

April 9, 2020

ViewRay and VieCure Announce Strategic Collaboration to Accelerate Adoption of Personalized Cancer Care

ViewRay, Inc. announced today a strategic collaboration with VieCure, an artificial intelligence (AI) informatics company with a leading point-of-care clinical decision support platform and a comprehensive electronic medical record (EMR) in oncology. The collaboration is designed to drive personalized care and treatment to patients by educating oncology practices on both companies' precision oncology solutions. Through the alliance, clinicians will have access to ViewRay's MRIdian MRI-guided radiation therapy system and VieCure's VCurePrecision™ EMR platform. VCurePrecision provides a real-time decision-support system that combines clinical knowledge with patient data to assist oncologists in generating personalized treatment plans and managing a patient's care throughout his or her cancer therapy. ViewRay's MRIdian integrates MRI technology, radiation delivery, and proprietary software to locate, target, and track the position and shape of soft-tissue and tumors while radiation is delivered. MRIdian also offers a powerful gating feature that automatically controls the radiation beam throughout each treatment, turning it off if the tumor moves outside of the targeted treatment area. The combination of MRIdian and VCurePrecision offers a formidable comprehensive precision oncology solution. 

April 1, 2020

Enloe Medical Center Becomes First Community Hospital in Northern California to Purchase a MRIdian MRI-Guided Radiation Therapy System

CLEVELANDMarch 19, 2020 - ViewRay, Inc. announced today that Enloe Medical Center – an independent, nonprofit hospital in Chico, California– has entered into a master agreement for the purchase of a MRIdian MRI-guided radiation therapy system. Upon installation, Enloe Medical Center will become the first community hospital in Northern California to offer MRIdian treatments. Enloe Medical Center is affiliated with the UCSF Helen Diller Family Comprehensive Cancer Center, an affiliation aimed at enhancing care and improving access to medical experts and high-quality, specialty treatment for residents throughout the region. Enloe's program integrates all facets of cancer care in a patient-centered environment using leading-edge technologies.

March 19, 2020

Ludwig-Maximilians-University Hospital Begins Patient Treatments with ViewRay’s MRIdian Linac

CLEVELANDMarch 18, 2020 - ViewRay, Inc. announced today that Ludwig-Maximilians-University Hospital in Munich has begun patient treatments with MRIdian® Linac, a cutting-edge radiation therapy system that combines the latest innovations in precision radiation delivery and ground-breaking MRI-guidance.   The first patient treated at Ludwig-Maximilians-University Hospital was treated for an ultra-central lung lesion using stereotactic body radiation therapy (SBRT), which delivers high doses of radiation to targeted areas in fewer treatment sessions than conventional radiation therapy. The goal of SBRT is to irradiate the tumor, mitigate side effects and impact to healthy surrounding tissue, and provide greater convenience to patients. Because of MRIdian's continual MRI-guided adaptive capabilities and automatic beam gating, it is well-suited to deliver SBRT treatments.

March 18, 2020

ViewRay Reports Fourth Quarter and Full Year 2019 Results

CLEVELANDMarch 12, 2020 - ViewRay, Inc. today announced financial results for the fourth quarter and full year ended December 31, 2019. A supplemental presentation for today's conference call is included on the Company's website at http://investors.viewray.com/events/event-details/q4-2019-viewray-inc-earnings-conference-call.   Full Year 2019 Highlights:

  • Total revenue of $87.8 million compared to 2018 revenue of $81.0 million, which is primarily from 15 revenue units including two system upgrades in each respective year.
  • Received 22 new orders for MRIdian systems, including three upgrades, totaling $118.5 million, compared to 23 new orders totaling $140.7 million in 2018.
  • Total backlog increased to $227.3 million as of December 31, 2019, compared to $212.3 million as of December 31, 2018.
  • Cash and cash equivalents were $226.8 million as of December 31, 2019. The Company received aggregate net proceeds of $138.4 million, after deducting underwriting discounts and commissions and offering expenses payable by the Company, from its December 2019 offering.
Fourth Quarter 2019 Summary:
  • Total revenue was $16.5 million in the quarter, primarily from three revenue units including one system upgrade, compared to $20.7 million, primarily from four revenue units including one system upgrade, for the same period last year.
  • Received four new orders for MRIdian systems totaling approximately $21.2 million in the fourth quarter of 2019, compared to eight new orders for MRIdian systems totaling approximately $48.7 million for the same period last year.
"In 2019 we built significant organizational expertise, made progress on our innovation and clinical pipelines, and fortified our balance sheet," said Scott Drake, President and CEO. "As we look at 2020, our commercial and operational activities are being impacted by the coronavirus and may be further impacted depending upon how the situation unfolds. As we look beyond the coronavirus uncertainty, we are confident in the capabilities we have built and how MRIdian is positioned to improve the paradigm of care."

March 12, 2020

ViewRay Announces Conference Call and Webcast of Fourth Quarter and Full Year 2019 Financial Results to be Held After Market on March 12, 2020

CLEVELANDFeb. 13, 2020 /PRNewswire/ -- ViewRay, Inc. announced today details relating to the release of its fourth quarter and full-year 2019 financial results.   ViewRay will hold a conference call to discuss results on Thursday, March 12, 2020 at 4:30 p.m. ET / 1:30 p.m. PT. The dial-in numbers are (844) 277-1426 for domestic callers and (336) 525 -7129 for international callers. The conference ID number is 6095383. A live webcast of the conference call will be available on the investor relations page of ViewRay's corporate website at www.viewray.com.   After the live webcast, a replay of the webcast will remain available online on the investor relations page of ViewRay's corporate website, www.viewray.com, for 14 days following the call. In addition, a telephonic replay of the call will be available until March 19, 2020. The replay dial-in numbers are (855) 859-2056 for domestic callers and (404) 537-3406 for international callers. Please use the conference ID number 6095383.

February 14, 2020

ViewRay Announces Preliminary Fourth Quarter and Full Year 2019 Results

CLEVELANDJan. 13, 2020 - ViewRay, Inc. today announced preliminary results for the fourth quarter and full fiscal year ended December 31, 2019. The preliminary results have not been audited and are subject to change.   Selected Fourth Quarter and Full Year 2019 Preliminary Results:

  • Total revenue of approximately $17 million in the fourth quarter of 2019, primarily from three revenue units including one system upgrade, compared to total revenue of $21 million, primarily from four revenue units including one system upgrade, in the fourth quarter of 2018.
  • Received four new orders for MRIdian systems totaling approximately $21 million in the fourth quarter of 2019, compared to eight new orders totaling approximately $49 million in the fourth quarter of 2018.
  • Full-year 2019 revenue of approximately $88 million, primarily from 15 revenue units, including two system upgrades, compared to 2018 revenue of approximately $81 million, primarily from 15 revenue units, including two system upgrades.
  • Total backlog was approximately $227 million as of December 31, 2019.
  • Cash and cash equivalents were approximately $227 million as of December 31, 2019. Cash burn in the fourth quarter of 2019, excluding the impact of the December 2019 financing, was approximately $3 million.
  • Chief Commercial Officer Jim Alecxih will be leaving the company effective January 17, 2020. At this time the company does not intend to backfill the Chief Commercial Officer role.
"In 2019 we built significant organizational expertise, made progress on our innovation and clinical pipelines, and fortified our balance sheet," said Scott Drake, President and CEO. "We are now better positioned than ever to improve the treatment paradigm for cancer patients. Today we also announced that Jim Alecxih, our Chief Commercial Officer, will be leaving the company to pursue other opportunities. We thank Jim for his service."

January 13, 2020

Michigan Community Hospital Begins Patient Treatments with ViewRay’s MRIdian Linac

ViewRay, Inc. announced today that Sparrow Health System in Lansing, Michigan has begun patient treatments with MRIdian® Linac, a cutting-edge radiation therapy system that combines the latest innovations in precision radiation delivery and ground-breaking MRI-guidance. The MRIdian device is located in the hospital's new Herbert-Herman Cancer Center, designed to deliver convenient and comprehensive patient care.

December 19, 2019

First MRIdian MRI-Guided Radiotherapy Treatments Begin in the United Kingdom

ViewRay, Inc. announced today that the first MRIdian MRI-guided radiotherapy system in the United Kingdom (UK) – located at GenesisCare Oxford – has begun patient treatments. MRIdian combines high definition MRI imaging with linear accelerator radiation therapy to allow clinicians to visualize and adapt therapy as they treat tumors throughout the body.

December 17, 2019

ViewRay Announces Full Exercise of Underwriters’ Option to Purchase Additional Shares and Closing of Public Offering of Common Stock

ViewRay, Inc., maker of the MRIdian, which combines MRI and external-beam radiation therapy to simultaneously image and treat cancer patients, today announced the completion of its previously announced underwritten public offering of 47,782,500 shares of common stock at a price to the public of $3.13 per share, for gross proceeds of approximately $149.6 million, before deducting underwriting discounts and commissions and estimated offering expenses payable by ViewRay.  All of the shares sold in the offering were sold by ViewRay. The shares sold included the full exercise of the underwriters' option to purchase additional shares.

December 6, 2019

ViewRay Announces Proposed Public Offering of Common Stock

ViewRay, Inc. (Nasdaq: VRAY), maker of the MRIdian, which combines MRI and external-beam radiation therapy to simultaneously image and treat cancer patients, today announced that it has commenced an underwritten public offering of $75.0 million of shares of its common stock.  In addition, ViewRay expects to grant the underwriters a 30-day option to purchase up to an additional $11.25 million of shares of common stock at the public offering price, less the underwriting discounts and commissions.  All of the shares of common stock to be sold in the offering will be offered by ViewRay.  The offering is subject to market and other conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering.

December 2, 2019

ViewRay Announces Collaborations with Elekta and Medtronic

ViewRay, Inc. announced today that it has signed a non-binding memorandum of understanding for collaboration with Elekta AB to advance the knowledge and use of MR-guided radiation therapy. In connection with the collaboration, Elekta has committed to invest capital for up to a 9.9% minority interest in ViewRay, subject to the terms and conditions set forth in a commitment agreement. Additionally, ViewRay has signed a non-binding memorandum of understanding with Medtronic (NYSE: MDT) to enter into a clinical collaboration in an area of mutual interest that includes exploring the clinical benefits of the MRIdian MR-guided radiation therapy system. In connection with the collaboration, Medtronic has committed to invest in a minority interest in ViewRay, subject to the terms and conditions set forth in a commitment agreement. ViewRay’s largest shareholder, Fosun International Limited (“Fosun”), has also committed capital up to an amount that would enable it to maintain its current beneficial ownership percentage in ViewRay, subject to the terms and conditions set forth in a commitment agreement.  

December 2, 2019

ViewRay to Present at the 2019 Piper Jaffray 31st Annual Healthcare Conference

ViewRay, Inc. today announced that the Company will participate in the 2019 Piper Jaffray 31st Annual Healthcare Conference in New York, New York. Scott Drake, President and CEO, will give a presentation at 1:30 p.m. Eastern Time on Wednesday, December 4, 2019.

November 20, 2019

ViewRay Reports Third Quarter 2019 Results

ViewRay, Inc. (Nasdaq: VRAY) today announced financial results for the third quarter ended September 30, 2019.   Third Quarter 2019 Summary:

  • Total revenue was $20.9 million in the quarter, primarily from three revenue units, compared to $17.7 million, primarily from three revenue units, for the same period last year.
  • Received eight new orders for MRIdian systems, including three upgrades, totaling approximately $35 million in the third quarter of 2019, compared to orders totaling approximately $36 million for the same period last year.
  • Total backlog grew to $230.7 million as of September 30, 2019, compared to $200.9 million as of September 30, 2018.
  • Cash and cash equivalents were $90.8 million as of September 30, 2019.
  • The Company reaffirmed its full year 2019 guidance of revenue in the range of $80 million to $95 million, and cash use in the range of $80 million to $90 million.
  “I am pleased with our Q3 results and the progress we are making across the organization,” said Scott Drake, President and CEO. “Our differentiation in the market is rooted in unparalleled innovation and clinical data.”

November 12, 2019

European Symposium to Advance Adoption of MRI-Guided Radiation Therapy

Clinicians interested in learning more about MRI-guided radiation therapy can attend a day-long symposium on Thursday, November 14, 2019 in Rome to understand the strategic, economic, clinical and technical aspects of starting an MR-image guided radiation therapy program. The Symposium will feature presentations from various experts in MRI-guided radiation therapy and an update on the Health Economics in Radiation Oncology Project (HERO), titled “Access to Innovative Radiotherapy: How to Make it Happen from an Economic Perspective,” given by co-chair and past president of the European Society for Radiotherapy and Oncology (ESTRO), Professor Yolande Lievens.

October 24, 2019

ViewRay Announces Preliminary Third Quarter 2019 Results and Details of Upcoming Conference Call

ViewRay, Inc. (NASDAQ: VRAY) today announced preliminary results for the third quarter 2019. The preliminary results have not been audited and are subject to change. Selected Third Quarter Preliminary Results:

  • Total revenue of $20.9 million in the third quarter of 2019, primarily from three revenue units, compared to total revenue of $17.7 million, primarily from three revenue units, in the third quarter of 2018.
  • Received 8 new orders for MRIdian systems, including 3 upgrades, totaling approximately $35 million in the third quarter of 2019, compared to orders totaling approximately $36 million in the third quarter of 2018.
  • Total backlog grew to approximately $231 million as of September 30, 2019.
  • Cash and cash equivalents were approximately $92 million as of September 30, 2019.
The Company reaffirmed its full year 2019 guidance of revenue in the range of $80-95 million, and cash use in the range of $80-90 million.

October 15, 2019

Patient Treatments with ViewRay’s MRIdian Linac Begin in New England

ViewRay, Inc. (Nasdaq: VRAY) announced today that patient treatments are scheduled to begin in Boston with ViewRay's MRIdian® Linac System at Dana-Farber/Brigham and Women's Cancer Center. The MRIdian provides for the delivery of radiation therapy to targeted tumors while simultaneously providing continuous magnetic resonance imaging (MRI).

October 7, 2019

Bestselling Author Dean Koontz And Gerda Koontz Give $9M To Hoag To Transform Radiation Oncology Care

Hoag grateful patient and author Dean Koontz and his wife, Gerda, long-time donors, have graciously committed $9 million to transform cancer care in Orange County. In recognition, Hoag is naming the Dean & Gerda Koontz Radiation Oncology Center in their honor. Through the couple's generosity, Hoag will be the only hospital in Orange County, and one of only two in California, to introduce the ViewRay MRIdian©, the world's first MRI-guided radiation therapy system. The MRIdian uses next generation technology to combine a diagnostic quality MRI scanner with a radiation linear accelerator. This allows for streaming real-time imaging of the radiation target and surrounding critical structures while a patient is being treated, a capability which has not been available to doctors previously.

September 16, 2019

Penn State Health Enters into Master Purchase Agreement with ViewRay for MRIdian® Systems

ViewRay, Inc. (NASDAQ: VRAY) announced today that Penn State Health has entered into a master agreement for the purchase of up to four MRIdian systems, placing an order for its first system today. Penn State Health, which includes the Milton S. Hershey Medical Center and St. Joseph Medical Center, has selected MRIdian to offer personalized, precise radiation therapy in its community centers, delivering world-class care to the patients it serves.

September 16, 2019

ViewRay Announces Collaboration with Stanford Health Care

ViewRay, Inc. (NASDAQ: VRAY) announced today that Stanford Health Care in Stanford, California, will acquire a MRIdian, the world’s leading MR-guided radiation therapy system. Stanford Health Care is internationally renowned for its expertise in cancer treatment and translating important medical breakthroughs into patient care. As a leading academic medical center, Stanford Health Care provides state-of-the-art technologies and treatments to help advance care and improve outcomes for patients.

September 12, 2019

Leading Radiation Oncology Meeting to Feature Unique Capabilities and Compelling Patient Outcomes with ViewRay’s MRIdian

ViewRay, Inc. (Nasdaq: VRAY) announced today that the company’s MRIdian® and MRIdian Linac MRI-guided radiation therapy systems will be featured at the 2019 Annual Meeting of the American Society for Radiation Oncology (ASTRO), being held September 15-19, 2019 in Chicago. The meeting will feature a number of presentations highlighting the unique capabilities, clinical experience and patient outcomes with ViewRay’s MRIdian and MRIdian Linac.

September 10, 2019

ViewRay to Host Investor Meeting at 2019 ASTRO Annual Meeting in Chicago

ViewRay, Inc. (Nasdaq: VRAY) today announced that the Company will host a physician-led informational discussion for investors and analysts during the 2019 American Society of Radiation Oncology (ASTRO) Annual Meeting in Chicago. Space is limited. Please RSVP to Kathleen Marvin at kmarvin@viewray.com to attend the meeting in person. Date: Monday, September 16, 2019 Time:  7:00 a.m. CT, Registration and breakfast, 7:30 to 9:00 a.m. CT, Physician-led informational discussion Location: Hyde Park Room at the Hyatt Regency McCormick Place, Chicago Guest Speakers: Dr. Percy Lee, Professor and Vice Chair of Education for the Department of Radiation Oncology, David Geffen School of Medicine at UCLA Dr. Ben Slotman, Professor and Chairman of the departments of Radiation Oncology, Amsterdam University Medical Centers, Amsterdam, The Netherlands.

August 27, 2019

ViewRay Announces Results of the First Prospective Clinical Trial on MR-guided Radiation Treatment for Prostate Cancer Without Implanted Markers

CLEVELAND, August 19, 2019 — ViewRay, Inc. (Nasdaq: VRAY) announced today the acceptance of publication by the International Journal of Radiation Oncology, Biology and Physics of the first prospective clinical trial of MR-guided radiation therapy (MRgRT) in patients with localized prostate cancer. This robust study of clinician and patient reported outcomes demonstrated zero CTCAE v4 grade 3 or higher gastrointestinal (GI) and genitourinary (GU) toxicity and even lower incidence of grade 2 toxicity than investigators hypothesized. It is also one of the first prospective clinical trials to study SBRT in a mix of intermediate- and high-risk prostate cancer patients, a challenging patient population to treat. The journal is the official scientific journal of the American Society for Radiation Oncology.

Researchers from Amsterdam University Medical Centers enrolled 101 patients with intermediate- or high-risk prostate cancer in a prospective phase II clinical trial. All patients received MRgRT in five fractions of 7.25 Gy to the target volume using on-table adaptive techniques. The trial did not use implanted markers or tissue spacers because treatments were delivered under MR-guidance, thereby eliminating an invasive procedure, potentially associated complications, and implantation costs

August 19, 2019

ViewRay® to Participate in Upcoming Investor Conferences

ViewRay, Inc. (NASDAQ: VRAY) today announced that the Company will participate in two upcoming investor conferences in New York, NY. Event:  Baird 2019 Global Healthcare Conference Format:  Fireside Chat & 1x1 Meetings Date: Wednesday, September 4, 2019 Time: 9:40 am ET Location:  Intercontinental New York Barclay   Event: Morgan Stanley 17thAnnual Global Healthcare Conference Format: Fireside Chat & 1x1 Meetings Date: Wednesday, September 11, 2019 Time: 1:35 pm ET Location: Grand Hyatt New York An audio webcast of the Company’s presentations will be available on the events and webinars section of ViewRay’s investor relations website at http://investors.viewray.com/events-and-presentations/upcoming-events. A replay of each webcast will be available for 14 days after the date of the presentation.

August 15, 2019

ViewRay Reports Second Quarter 2019 Results

CLEVELAND, August 8, 2019 — ViewRay, Inc. (Nasdaq: VRAY) today announced financial results for the second quarter ended June 30, 2019. Second Quarter 2019 Summary:

  • The Company is updating 2019 guidance and now anticipates total revenue in the range of $80 million to $95 million, and total cash usage to be in the range of $80 million to $90 million.
  • Total revenue was $30.2 million in the quarter, primarily from 5 revenue units, compared to $16.4 million, primarily from 3 revenue units, for the same period last year.
  • Received 3 new orders in the quarter for MRIdian systems totaling $18.1 million, compared to orders totaling $6 million for the same period last year.
  • Total backlog was $219.3 million as of June 30, 2019, compared to $199.7 million as of June 30, 2018.
  • Cash and cash equivalents were $122.1 million as of June 30, 2019.
  • Chief Financial Officer Ajay Bansal will be leaving the company effective September 30, 2019.

August 8, 2019

ViewRay Announces Conference Call and Webcast of Second Quarter 2019 Financial Results to be Held After Market on August 8, 2019

ViewRay, Inc. (Nasdaq: VRAY) announced today details relating to the release of its second quarter 2019 financial results. ViewRay will hold a conference call to discuss results on Thursday, August 8, 2019 at 4:30 p.m. ET / 1:30 p.m. PT. The dial-in numbers are (844) 277-1426 for domestic callers and (336) 525-7129 for international callers. The conference ID number is 1695303. A live webcast of the conference call will be available on the investor relations page of ViewRay's corporate website at www.viewray.com.

July 18, 2019

ViewRay Announces Appointment of Dr. Gail Wilensky to its Board of Directors

CLEVELAND, July 16, 2019 /PRNewswire/ -- ViewRay, Inc. (Nasdaq: VRAY) announced the appointment of Dr. Gail Wilensky to its Board of Directors, effective today. Dr. Wilensky has an extensive track record in healthcare as a policy leader, reimbursement expert, and board member. She is currently a Senior Fellow at Project HOPE, an international non-profit health foundation. She served in the White House as a senior adviser on health and welfare issues to President George H.W. Bush and directed the Medicare and Medicaid programs. Gail was also the first chair of the Medicare Payment Advisory Commission.

July 16, 2019

Leading Medical Physics Meeting to Feature More than 40 Presentations on ViewRay’s MRIdian MRI-Guided Radiotherapy

ViewRay, Inc. (Nasdaq: VRAY) announced today that the company’sMRIdian® System is the focus of more than 40 abstracts selected by the American Association of Physicists in Medicine (AAPM) for presentation during their 2019 Annual Meeting. AAPM is the largest association of medical physicists in the world, and this year’s annual meeting will be held July 14-18 in San Antonio, Texas.

July 10, 2019

World’s First MRIdian Center Treats 1,000th Patient with MRI-Guided Radiation Therapy

ViewRay, Inc. (Nasdaq: VRAY) announced today that the clinical team at Siteman Cancer Center at Barnes-Jewish Hospital and Washington University School of Medicine in St. Louis has treated its 1,000th patient using MRIdian MR-guided radiation therapy. Siteman Cancer Center helped pioneer MR-guided radiation therapy, becoming the first center to treat patients with MRIdian in January 2014. Siteman also leads the industry as the first to perform adaptive radiation therapy under MR-guidance. MRIdian's on-table adaptive capability and automated beam gating, now routinely practiced at Siteman, allows clinicians to personalize the radiation delivery by adapting to daily changes in a patient's anatomy, while its real-time tissue tracking and beam control allow greater precision to the delivery of radiation therapy. As the use of MR-guided radiation therapy expanded, Siteman acquired a second MRIdian System – the MRIdian Linac – in November 2017, following FDA-clearance of this next-generation technology from ViewRay. The new technology features MRI-guidance combined with linear accelerator delivery.

May 22, 2019

ViewRay® to Present at the Jefferies 2019 Global Healthcare Conference

ViewRay, Inc. (NASDAQ: VRAY) today announced that the Company will participate in the Jefferies 2019 Global Healthcare Conference in New York, New York. Scott Drake, President and CEO, will participate in a fireside chatat 8:30 a.m. Eastern Time on Thursday, June 6, 2019. An audio webcast of the Company’s presentation will be available on the investor relations section of ViewRay’s website at www.viewray.com. A replay of the webcast will be available for 7 days after the date of the presentation.

May 16, 2019

ViewRay Reports First Quarter 2019 Results

ViewRay, Inc. (Nasdaq: VRAY) today announced financial results for the first quarter ended March 31, 2019. First Quarter 2019 Highlights:

  • Received 7 new orders for MRIdian systems totaling $42.8 million, compared to 3 orders totaling $2 million in the first quarter of 2018.
  • Total revenue of $20.3 million, primarily from 3 revenue units and 1 system upgrade, compared to $26.2 million, primarily from 4 revenue units and 1 system upgrade, in the first quarter of 2018.
  • Total backlog increased to $237.5 million as of March 31, 2019, from $212.3 million as of December 31, 2018.
  • Cash and cash equivalents were $145.8 million as of March 31, 2019.

May 2, 2019

ViewRay’s MRIdian to be Featured at Leading European Radiation Oncology Meeting

ViewRay, Inc. (Nasdaq: VRAY) announced today that the company’s MRIdian MRI-guided radiation therapy system will be featured at the Annual Meeting of the European Society for Radiotherapy and Oncology (ESTRO), with a number of presentations and posters highlighting MRIdian research and clinical experience. The ESTRO meeting will be held April 26-30 in Milan, Italy. Please visit https://go.viewray.com/ESTRO_2019 for a detailed schedule of MRIdian presentations, posters and in-booth speakers.

April 23, 2019

ViewRay Partners with Leading Canadian Distributor to Bring MRI-guided Radiation Therapy to Canada

ViewRay, Inc. (Nasdaq: VRAY) announced today that the company has partnered with Minogue Medical Inc., a leading Canadian distributor of surgical devices, operating room disposables, hospital equipment, and simulators for medical education. As part of the exclusive distribution agreement, Minogue Medical will market, sell, and support ViewRay’s MRIdian MRI-guided radiation therapy system throughout Canada.

April 18, 2019

ViewRay Partners with Largest Independent Distributor in Australia and New Zealand to Bring Benefits of MRI-Guided Radiation Therapy to the Region

ViewRay, Inc. (Nasdaq: VRAY) and Device Technologies Australia Pty Ltd (Device Technologies) announced today a partnership in which Device Technologies, the largest independent distributor in Australasia, will market, sell, and support ViewRay’s MRIdian MRI-guided radiation therapy system. "Device Technologies is the ideal partner to bring the benefits of the MRIdian System to one of the biggest and best healthcare markets in the world,” said Jim Alecxih, Chief Commercial Officer at ViewRay. “Device Technologies has successfully sold, implemented and supported many other high-tech medical devices, so we’re confident given the growing excitement around MRI-guided radiation therapy, that they will deliver equally impressive results with MRIdian.”

April 17, 2019

ViewRay Announces Publication of Retrospective Study on MR-guided Radiation Treatment for Locally Advanced Pancreatic Cancer

ViewRay, Inc. (Nasdaq: VRAY)announced today the publication of a retrospective analysis of outcomes for the stereotactic treatment of locally advanced pancreatic cancer using precise, high-dose MRI-guided radiation therapy delivered with MRIdian’s on-table adaptive dose planning system. The study, published in Cancer Medicine, and led by Soumon Rudra, M.D. from Washington University in St. Louis, demonstrated enhanced overall survival while resulting in lower levels of toxicity compared to lower-dose, mostly non-adaptive treatment. These outcomes inspired the ongoing SMART trial, a multi-institutional prospective trial intended to assess the outcomes of this retrospective analysis further.

April 11, 2019

ViewRay Reports Fourth Quarter and Full Year 2018 Results

CLEVELAND, March 14, 2019 — ViewRay, Inc. (Nasdaq: VRAY) today announced financial results for the fourth quarter and full year ended December 31, 2018.   Full Year 2018 Highlights:

  • Total revenue of $81.0 million, primarily from 13 revenue units and 2 system upgrades, compared to 2017 revenue of approximately $34.0 million, primarily from 6 revenue units.
  • Received 23 new orders for MRIdian systems totaling $140.7 million, up from 19 new orders totaling $113.6 million in 2017.
  • Total backlog increased to $212.3 million as of December 31, 2018, up from $203.6 million as of December 31, 2017.
  • Cash and cash equivalents were $167.4 million as of December 31, 2018.

March 14, 2019

MRI-Guided Radiation: A New Option for Pancreatic Cancer Treatment

Let’s Win! Pancreatic Cancer / Lustgarten Foundation, February 28, 2019: Pancreatic cancer has long presented a challenge to radiation oncologists, who are barely able to see the tightly-protected organ, never mind deliver sufficient doses of radiation without causing collateral damage to the organ’s delicate neighbors. A new therapy being tested at a handful of locations across the United States may finally make radiation a viable option for people with locally advanced pancreatic cancer. Initial results show promising potential for improving survival rates. … Researchers at sites with this technology, such as UCLA (Los Angeles), Washington University, University of Miami, Miami Baptist University of Wisconsin, and Weill Cornell Medicine (New York), will enroll 133 patients with borderline resectable or inoperable locally advanced pancreatic cancer in a clinical trial.

February 28, 2019

ViewRay Announces FDA 510(k) Clearance for Advancements in MRI and Functional Imaging Technologies for MRIdian MRI-Guided Radiation Therapy System

CLEVELAND, Feb. 21, 2019 /PRNewswire/ -- ViewRay, Inc. (Nasdaq: VRAY), announced today that the company received 510(k) clearance from the U.S. Food and Drug Administration (FDA) to market new soft tissue visualization capabilities for its MRIdian system. The new upgradable capabilities enhance the industry-leading features of MRIdian's SmartVISION MRI, including: Expanded high-definition visualization and enhanced contrast between different tissues, to assist clinicians with tissue visualization and beam contouring The potential to aid in the assessment and prediction of tumor response to radiation therapy is enabled by "DWI", our diffusion weighted imaging feature which tracks treatment progress by distinguishing between tumor and normal tissues Faster, brighter, more detailed anatomical planar imaging to strike tumors with greater precision and accuracy through our proprietary technology, which allows for a 2X increase in MR imaging speed (to 8 frames per second), a 2X increase in image resolution, and a 2X improvement in MR signal-to-noise ratio (SNR) Potential reduction in treatment delivery time through enhanced MLC speed

February 21, 2019

ViewRay Announces Conference Call and Webcast of Q4 and Full Year 2018 Financial Results to be Held After Market on March 14, 2019

CLEVELAND, Feb. 14, 2019 – ViewRay, Inc. (Nasdaq: VRAY) announced today details relating to the release of its fourth quarter and full year 2018 financial results. ViewRay will hold a conference call to discuss results on Thursday March 14, 2019 at 4:30 p.m. ET / 1:30 p.m. PT. The dial-in numbers are (844) 277-1426 for domestic callers and (336) 525-7129 for international callers. The conference ID number is 7659688. A live webcast of the conference call will be available on the investor relations page of ViewRay's corporate website at www.viewray.wpengine.com.

February 14, 2019

World’s First MRIdian Center Celebrates Five Years of MRI-Guided Radiation Treatments

ViewRay, Inc. (Nasdaq: VRAY) announced today the five-year anniversary of patient treatments with MRIdian MRI-guided radiation therapy at Siteman Cancer Center at Barnes-Jewish Hospital and Washington University School of Medicine in St. Louis, Missouri. As one of the world’s leading cancer centers, Siteman is known for pioneering the advancement and adoption of innovative technologies with a focus on improving patient care and outcomes.

January 22, 2019

ViewRay Announces Preliminary Fourth Quarter and Fiscal Year 2018 Results

ViewRay, Inc. (Nasdaq: VRAY) today announced preliminary results for the fourth quarter and full fiscal year ended December 31, 2018. The preliminary results have not been audited and are subject to change. Selected Fourth Quarter and Full Year 2018 Preliminary Highlights:

  • Recognized 3 revenue units and 1 system upgrade in the fourth quarter of 2018. This resulted in total fourth quarter 2018 revenue of approximately $21 million, compared to fourth quarter 2017 revenue of $19.9 million, primarily from four revenue units.
  • Received 8 new orders for MRIdian systems totaling approximately $49 million in the fourth quarter of 2018, compared to orders totaling $34 million in the fourth quarter of 2017.
  • Full year 2018 revenue of approximately $81 million, primarily from 13 revenue units and 2 system upgrades, compared to 2017 revenue of approximately $34.0 million, primarily from 6 MRIdian systems.
  • Backlog as of December 31, 2018 grew to approximately $212 million.
  • Cash and cash equivalents were approximately $167 million as of December 31, 2018.

January 7, 2019

First Patient Enrolled in Stereotactic MRI-guided On-table Adaptive Radiation Therapy (SMART) Trial for Locally Advanced Pancreatic Cancer

ViewRay, Inc. (Nasdaq: VRAY) announced today the enrollment of the first patient in the Stereotactic MRI-guided On-table Adaptive Radiation Therapy (SMART) Trial, a multi-center, prospective clinical trial for locally advanced or borderline resectable pancreatic cancer. The trial will explore the clinical benefits of precise, high dose radiation therapy enabled by MR-guidance combined with daily on-table adaptation in the treatment of pancreatic cancer. Retrospective analysis of precise, high-dose MR-guided radiation therapy delivered using adaptive dose planning has shown promising results with locally advanced pancreatic cancer, suggesting the potential for improving overall survival relative to patients receiving lower radiation doses, without increasing the rate of serious gastrointestinal toxicity. The compelling nature of the retrospective data prompted the SMART trial, aimed at investigating in a controlled, prospective manner, the robustness of this outcome and tracking quality of life over a 5-year trial period.

January 4, 2019

ViewRay® to Present at the 37th Annual J.P. Morgan Healthcare Conference

ViewRay, Inc. (NASDAQ: VRAY) today announced that the Company will present at the 37th Annual J.P. Morgan Healthcare Conference in San Francisco, California. Scott Drake, President and CEO, is scheduled to present at 8:30 a.m. Pacific Time on Wednesday, January 9, 2019. An audio webcast of the Company’s presentation will be available on the investor relations section of ViewRay’s website at www.viewray.wpengine.com. A replay of the webcast will be available for 7 days after the date of the presentation.  

December 10, 2018

Rob Fuchs joins ViewRay as Chief Human Resources Officer

ViewRay, Inc. announced today the appointment of Robert M. Fuchs as Chief Human Resources Officer effective October 22, 2018. Mr. Fuchs has over 18 years of experience in leading human resources. Prior to joining ViewRay, Rob was the Senior Vice President, Global Human Resources Officer for Advanced Energy. Previously, he served as Senior Vice President, Global Human Resources Officer for Spectranetics. "We are pleased to announce that Rob Fuchs has been named our Chief Human Resources Officer," said Scott Drake, President and CEO. "Attracting, developing, and retaining talent is a top priority for ViewRay. Rob will play an instrumental role in this objective, and his passion for people and performance make him an excellent addition to our company."

November 21, 2018

ViewRay® to Present at 30th Annual Piper Jaffray Healthcare Conference

ViewRay, Inc. (NASDAQ: VRAY) announced today that company management is scheduled to participate in a fireside chat at the 30thAnnual Piper Jaffray Healthcare Conference in New York, NY. Date:  Wednesday, November 28, 2018. Time: 12:30 – 12:55 pm ET. Location: Lotte New York Palace. An audio webcast of the Company’s fireside chat will be available on the investor relations section of ViewRay’s website at www.viewray.wpengine.com. A replay of the webcast will be available for 7 days after the date of the fireside chat

November 16, 2018

ViewRay Reports Third Quarter 2018 Results

ViewRay, Inc. (Nasdaq: VRAY) (“the Company”) today announced financial results for the third quarter ended September 30, 2018. Third Quarter 2018 Highlights:

  • Total revenue of $17.7 million, primarily from 3 revenue units.
  • Received new orders for MRIdian systems totaling $36.2 million. The backlog as of September 30, 2018 was $200.9 million.
  • The Company raised net proceeds of $161.9 million during the quarter from a common stock public offering.
“We have a tremendous opportunity to become the standard of care in radiation oncology. During the third quarter we made significant progress building our team and processes to capitalize, and much work lies ahead,” said Scott Drake, President and CEO.

November 8, 2018

ViewRay signs agreement with GenesisCare to bring the first MRIdian MRI-guided radiotherapy systems to the UK

ViewRay, Inc. (Nasdaq: VRAY) today announced a collaboration with GenesisCare, the largest provider of cancer services in the UK, Spain and Australia, to introduce the first MRIdian MRI-guided radiotherapy system in the UK to benefit cancer patients. As part of the formal agreement, multiple MRIdian linear accelerators will be deployed within the GenesisCare network, with the first two systems to be installed in the UK. MRIdian leverages the soft-tissue imaging capabilities of MRI to allow oncologists to visualize tumors and personalize treatment more accurately than is possible with conventional technology. The agreement will allow GenesisCare to advance its vision of precision radiation medicine by contributing to the evidence base for, and delivering, high quality image-guided, adaptive radiotherapy.

October 29, 2018

Real-Time Adaptive Radiotherapy Capabilities of ViewRay’s MRIdian Highlighted at Investor & Analyst Meeting at ASTRO 2018

ViewRay, Inc. (Nasdaq: VRAY) today announced highlights from its investor & analyst meeting during the annual meeting of the American Society for Radiation Oncology (ASTRO) in San Antonio, TX. The meeting featured presentations highlighting clinical experiences with the MRIdian System from leading radiation oncologists at the Moffitt Cancer Center and David Geffen School of Medicine at UCLA.

October 22, 2018

ViewRay Announces Conference Call and Webcast of Third Quarter 2018 Financial Results to be Held After Market on November 8, 2018

ViewRay, Inc. (Nasdaq: VRAY) announced today details relating to the release of its third quarter 2018 financial results, which will take place after the market close on Thursday, November 8, 2018. ViewRay will hold a conference call on Thursday November 8, 2018 at 4:30 p.m. ET / 1:30 p.m. PT to discuss the results. The dial-in numbers are (844) 277-1426 for domestic callers and (336) 525-7129 for international callers. The conference ID number is 6190699. A live webcast of the conference call will be available on the investor relations page of ViewRay’s corporate website at www.viewray.wpengine.com.

October 19, 2018

ASTRO 2018 Presentations to Feature Unique Capabilities and Clinical Outcomes of ViewRay’s MRIdian Next Generation Cancer Care

The company’s MRIdian® and MRIdian Linac – the world’s only FDA-cleared MRI-guided radiation therapy systems – will be featured at the Annual Meeting of the American Society for Radiation Oncology (ASTRO). ASTRO 2018 will be held October 21-24, 2018 in San Antonio, TX and will include a number of presentations highlighting the unique capabilities, clinical experience and patient outcomes.

October 16, 2018

ViewRay® to Host Investor & Analyst Meeting at 2018 ASTRO Annual Meeting in San Antonio

ViewRay, Inc. (NASDAQ: VRAY) announced today that the Company will hold a meeting for investors and analysts on Monday, October 22, 2018, (7:00 – 9:00 a.m. CT) during the annual meeting of the American Society for Radiation Oncology (ASTRO) in San Antonio, TX. The meeting will include a brief company update from Scott Drake, President and Chief Executive Officer of ViewRay, followed by presentations from Louis B. Harrison, M.D., FASTRO, Chair and Senior Member, Department of Radiation Oncology at Moffitt Cancer Center and Michael L. Steinberg, M.D., Professor and Chair, Department of Radiation Oncology at the David Geffen School of Medicine at UCLA.  

October 9, 2018

ViewRay Appoints Industry Veteran James Alecxih as Chief Commercial Officer

ViewRay, Inc. (Nasdaq: VRAY), maker of the MRIdian, which combines MRI and external-beam radiation therapy to simultaneously image and treat cancer patients, today announced the appointment of James “Jim” Alecxih as Chief Commercial Officer, effective September 17th, 2018. Mr. Alecxih joins the ViewRay leadership team with extensive experience in commercializing new and innovative devices globally and will be responsible for driving the Company’s commercial expansion.

October 3, 2018

MRI-Guided Radiation Therapy Aims to Prolong Survival and Reduce Complications for the Most Challenging Cancers

Leading oncology experts from around the world met to discuss the integration of magnetic resonance imaging (MRI) with radiation therapy and its potential to extend life expectancy and reduce common side effects in many cancer patients. ViewRay, Inc. (NASDAQ: VRAY), maker of MRIdian®, the world’s first and only FDA-cleared, MRI-guided radiation therapy system, and Miami Cancer Institute, co-hosted experts from research hospitals at the cutting-edge of cancer treatment at the September 28 symposium and panel discussion.

October 1, 2018

ViewRay® to Present at the 2018 Cantor Global Healthcare Conference

ViewRay, Inc. (NASDAQ: VRAY) announced today that members of the executive management team are scheduled to present at the Cantor Global Healthcare Conference in New York, NY on Tuesday, October 2, 2018. An audio webcast of the Company’s presentation will be available on the investor relations section of ViewRay’s website at www.viewray.wpengine.com. A replay of the webcast will be available for 7 days after the date of the presentation.

September 25, 2018

ViewRay Announces Equity Inducement Awards under Nasdaq Listing Rule 5635(c)(4)

ViewRay, Inc. (Nasdaq: VRAY), maker of the MRIdian, which combines MRI and external-beam radiation therapy to simultaneously image and treat cancer patients, today announced grants of stock options and restricted stock units to several new officers and employees. These awards were granted as inducements material to entering into employment with ViewRay, in accordance with Nasdaq Listing Rule 5635(c)(4) and as approved by the Compensation Committee of ViewRay’s Board of Directors.

September 17, 2018

Acibadem Maslak Hospital in Turkey Introduces Next Generation Cancer Care with MRIdian MR Image-Guided RT

ViewRay, Inc. (Nasdaq: VRAY) announced today that Acibadem Maslak Hospital in Istanbul, Turkey has begun treating patients with ViewRay’s MRIdian® Linac, the world’s first system to combine MRI guidance and linear accelerator radiation delivery. These treatments mark the first in Turkey using MRI-guided radiation therapy.

September 13, 2018

ViewRay Announces Pricing of Public Offering of Common Stock

ViewRay, Inc. (Nasdaq: VRAY), maker of the MRIdian, which combines MRI and external-beam radiation therapy to simultaneously image and treat cancer patients,today announced the pricing of an underwritten public offering of 16,216,217 shares of common stock at a price to the public of $9.25 per share, for gross proceeds of $150 million, before deducting underwriting discounts and commissions and estimated offering expenses payable by ViewRay. All of the shares to be sold in the offering will be offered by ViewRay. In addition, ViewRay has granted the underwriters of the offering a 30-day option to purchase up to an additional 2,432,432 shares of common stock at the public offering price, less underwriting discounts and commissions.

August 15, 2018

ViewRay Announces Proposed Public Offering of Common Stock

ViewRay, Inc. (Nasdaq: VRAY), maker of the MRIdian, which combines MRI and external-beam radiation therapy to simultaneously image and treat cancer patients, today announced that it has commenced an underwritten public offering of $125.0million of shares of its common stock. In addition, ViewRay expects to grant the underwriters a 30-day option to purchase up to an additional $18.75million of shares of its common stock at the public offering price, less the underwriting discounts and commissions. All of the shares of common stock to be sold in the offering will be offered by ViewRay. The offering is subject to market and other conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering.

August 14, 2018

ViewRay Reports Second Quarter 2018 Financial Results

ViewRay, Inc. (Nasdaq: VRAY) today announced financial results for the second quarter ended June 30, 2018. Total revenue for the second quarter ended June 30, 2018 was $16.4 million, compared to $0.7 million for the same period last year.  Revenue for the second quarter ended June 30, 2018 included 3 new MRIdian system installs or delivery, all recognized as product revenue.

August 3, 2018

Leading Medical Physics Meeting to Feature More than 50 Presentations on ViewRay’s MRIdian MRI-Guided Radiotherapy

ViewRay, Inc. (Nasdaq: VRAY), makers of the world’s only FDA-cleared MRI-guided radiation therapy system, announced today that the company’s MRIdian® System is the focus of 55 abstracts selected by the American Association of Physicists in Medicine (AAPM) for presentation during their 2018 Annual Meeting. AAPM is the largest association of medical physicists in the world, and this year’s meeting will be held July 29-August 2 in Nashville.

July 26, 2018

ViewRay Appoints Scott Drake as President, Chief Executive Officer and a Member of the Board of Directors, Shar Matin as Chief Operating Officer, and D. Keith Grossman as a Member of the Board of Directors

ViewRay, Inc. (Nasdaq: VRAY), maker of the market-leading MRI-guided radiation therapy system, announced today the appointment of medical device industry veterans Scott Drake as its President and Chief Executive Officer and Shar Matin as its Chief Operating Officer, effective immediately. In connection with his appointment, Mr. Drake has also been appointed to the ViewRay Board of Directors. In addition, ViewRay announced the appointment of D. Keith Grossman to the ViewRay Board of Directors. ViewRay Pre-Releases Preliminary Second Quarter 2018 Revenue of $16 Million and Reaffirms Revenue Guidance of $80 to $90 Million for 2018

July 25, 2018

Webinar: MR Image Guidance and On-Table Adaptive Radiotherapy in Routine Clinical Practice

Oncology professionals: Interested in learning how clinics have integrated MRI-Guided RT into their practice?  Watch the July 26th Webinar and hear from clinicians in Amsterdam and St. Louis, MO who, for several years, have been using real-time image guidance and on-table plan adaptation on the MRIdian® system. Webinar: ow.ly/AdFN30kVafc

July 23, 2018

ViewRay’s MRIdian Linac Awarded French Tender for MR Image-guided Radiation Therapy

ViewRay, Inc. (Nasdaq: VRAY) announced that the company’s MRIdian® Linac has been selected for installation at Centre Georges-François Leclerc (CGFL) in Dijon, France as part of a tender award contract with UNICANCER, a hospital network of 19 French Comprehensive Cancer Centers (FCCCs).

July 11, 2018

Loyola Medicine/Palos Health Installs ViewRay’s MRIdian Linac System for MR Image-Guided Radiation Therapy

ViewRay, Inc. (Nasdaq: VRAY)announced today that Palos Health, in partnership with Loyola Medicine, has installed ViewRay’s MRIdian® Linac System for MR image-guided radiation therapy at its Palos Health South Campus in Orland Park, Illinois. Palos Health becomes the first community hospital in the United States, and the only center in Illinois with the company’s next generation linear accelerator-based system.

July 9, 2018

Nearly 200 Oncology Experts Gather to Discuss Advanced Applications of MR Image-Guided Radiotherapy

The symposium, titled “Advanced Applications of MR-Guided Radiotherapy Symposium,” brought together nearly 200 members of the global oncology community, including radiation oncologists and medical physicists, for talks on various aspects of MR image-guided radiation therapy presented by five experts in the field.

June 21, 2018

University of Wisconsin Begins Patient Treatments with ViewRay’s MRIdian Linac

University of Wisconsin Carbone Cancer Center in Madison, Wisconsin, has begun patient treatments with the company’s MRIdian® Linac, following an upgrade of the hospital’s original MRIdian System. The next-generation MRIdian Linac combines the benefits of MR-image guidance with linear accelerator radiation delivery for the precision treatment of cancer.

June 21, 2018

Pioneer of MR Image-Guided Radiotherapy, Washington University, Begins First Clinical Treatments with its Second ViewRay MRIdian System

The Siteman Cancer Center at Barnes-Jewish Hospital and Washington University School of Medicine in St. Louis, Missouri, is treating patients with the company’s second-generation MR image-guided radiotherapy system, the MRIdian® Linac. Siteman is the first U.S. cancer center to offer cancer therapy with both MRIdian and MRIdian Linac, furthering its leadership role in MR image-guided radiation therapy.

June 13, 2018

ViewRay’s Chris Raanes on Bloomberg-Radio

Listen to the Bloomberg-Radio segment

 

June 11, 2018

World-Leading Oncologists to Meet in Miami for Adaptive MR Image-Guided Radiotherapy Symposium

Experts in MR image-guided radiation therapy will share their experiences during an educational symposium to be held on Friday, September 28, 2018 in Miami. The event aims to facilitate clinical and scientific discovery, as well as educate clinicians interested in the novel advancements of MR image-guided radiation therapy for treating cancer.

May 23, 2018

ViewRay’s Clinical Cooperative Think Tank Convenes to Discuss Clinical Experience and Further Trial Development for MRIdian MR-Image Guided Radiotherapy

ViewRay, Inc. (Nasdaq: VRAY) announced today that members of its Clinical Cooperative Think Tank (C2T2) gathered last week in Barcelona, Spain to discuss data from the nearly 3,000 patients treated using ViewRay’s MRIdian MR image-guided radiotherapy system. The group also evaluated new clinical opportunities and potential future trials for this novel technology.

May 2, 2018

ViewRay Finalizes Order for MR Image-Guided Radiation Therapy System at University Hospital Zurich

ViewRay, Inc. (Nasdaq: VRAY) announced today an order for the company’s MRIdian® MR image-guided linac at the University Hospital Zurich (USZ) in Zurich, Switzerland. The order formalizes the previously announced tender award from the Swiss National R’Equip programme. Once commissioned, the USZ MRIdian system will be the first in Switzerland, and among the first MR-guided linac systems in Europe to treat patients.

March 14, 2018

Simultaneous Tumor Tracking and Treatment Delivers Precise, Accurate Radiation

The Henry Ford Cancer Institute is the first in the world to offer patients an advanced radiation therapy that uses an FDA-approved real-time magnetic resonance imaging (MRI) to deliver more precise and accurate radiation treatment using a linear accelerator. With this new system, called ViewRay MRIdian Linac®, it is now possible to image the treatment area and deliver radiation at the same time -- more effectively protecting surrounding healthy tissue. Watch the Spotlight on Innovation: MRI-Guided Radiation Therapy segment.

November 1, 2017

Cureus Launches Case Report Publishing Competition Aimed at Advancing MR-Guided Radiation Therapy

Competition Seeks to Document MR-Guided Radiotherapy Clinical Applications and Experiences to Increase Information Sharing and Help Improve Cancer Care The Cureus Journal of Medical Science announced today the start of a medical case report publishing competition aimed at advancing the clinical practice of MR-guided radiation therapy by documenting clinical applications and experience and sharing the information freely with the oncology community...All eligible submissions will undergo an independent pre-publication peer review conducted by a world-class team of radiation oncology and medical physics experts; and, three monetary prizes will be awarded to the published articles that receive the highest Cureus SIQ rating. Click the title to view the complete press release from The Cureus Journal of Medicine.

September 28, 2017

ViewRay MRIdian to be Featured in 21 Presentations from Seven Leading Centers at ASTRO

The company's MRIdian and MRIdian Linac systems will be featured at the Annual Meeting of the American Society for Radiation Oncology (ASTRO), with a number of presentations highlighting clinical experience and patient outcomes. The ASTRO meeting will be held September 24-27, 2017 in San Diego. MR-guided radiation therapy remains a significant area of interest, as reflected by the 21 MRIdian clinical presentations and posters accepted as part of ASTRO's Scientific Sessions.

September 21, 2017

MRIdian Linac purchased by Institut du Cancer Montpellier (ICM).

Bringing the benefits of soft-tissue visualization and adaptive therapy to cancer patients throughout France. http://france3-regions.francetvinfo.fr/occitanie/herault/montpellier/radiotherapie-irm-embarquee-cibler-tumeurs-montpellier-fin-2018-1328773.html  

September 16, 2017

Miami Cancer Institute to Acquire ViewRay’s MRIdian Linac for MRI-Guided Radiation Therapy

Miami Cancer Institute, part of Baptist Health South Florida, announced today that it will acquire ViewRay’s MRIdian Linac System, the world’s first and only FDA-cleared MRI-guided radiation therapy system. The MRIdian system will be part of the healthcare organization’s new Miami Cancer Institute, a multidisciplinary, destination cancer center and member of the Memorial Sloan Kettering Cancer Alliance. The MRIdian treatments are expected to be available for patient care in spring 2018.

July 27, 2017

Henry Ford Treats World’s First Patient Using New MRI-Guided Radiation Therapy that Simultaneously Tracks, Treats Tumor

The Henry Ford Cancer Institute has treated the world’s first cancer patient today with an advanced radiation therapy that uses an FDA-cleared real-time magnetic resonance imaging and linear accelerator delivery for more precise and accurate radiation treatment.

July 19, 2017

Orlando Health’s new $30M cancer center to have the latest technology

The new Orlando Health UF Health Cancer Center – Ocoee in Health Central hospital will use Central Florida's latest cancer-tracking technology called MRIdian.

The cutting-edge technology provides a combination of simultaneous radiation therapy and magnetic resonance imaging (MRI) for cancer treatment.

 

June 28, 2017

Moffitt Cancer Center Targets Tumors by Using More Precise Radiation Method

Moffitt Cancer Center recently signed a deal to acquire ViewRay’s MRIdian Linac System, the world’s first and only FDA-cleared MRI-guided radiation therapy system, to assist with precision radiation. MRIdian Linac provides a unique combination of simultaneous radiation therapy delivery and continuous magnetic resonance imaging (MRI) for the treatment of cancer.

June 27, 2017

Two-and-a-half-year clinical experience with the world’s first magnetic resonance image guided radiation therapy system

The first MRI-guided radiation treatment took place in January 2014, at the Siteman Cancer Center at Barnes-Jewish Hospital and Washington University School of Medicine. The treatment was performed using ViewRay's MRIdian, which integrates a 0.35 T MRI with three gamma-emitting cobalt-60 sources. We report on more than 2 years of clinical experience in treating patients with the world's first MR-IGRT system.

June 1, 2017

ViewRay on Fox News

Watch watch ViewRay on Fox Business “Mornings with Maria” – Aired March 3, 2017 (7 min 58 sec.)

March 3, 2017

ViewRay on CNBC Power Lunch

Watch ViewRay on CNBC-TV’s “Power Lunch” – Aired March 2, 2017 (2 min 17 sec)

March 2, 2017

MRI-Guided Radiation More Precise

Doctors say a medical breakthrough in radiation delivery is ensuring they hit their tumor targets. It also means less toxicity to the surrounding healthy tissue. Here are more details on this high-tech tool that is helping doctors battle cancer at Sylvester Comprehensive Cancer Center in Miami, Florida.

September 26, 2016

MRIdian Making Headlines in Dutch News

VUmc, Amsterdam and MRIdian have been featured on two Dutch news channels: Watch NOS Journaal Video Watch editieNL Video

July 10, 2016

MRIdian Featured on ABC Los Angeles

MRIdian used to treat patient at UCLA - watch Lori’s story and interview with UCLA’s Dr. Percy Lee. Watch the KABC-TV segment

July 1, 2016

SNNLive spoke with Chris A. Raanes, President and CEO of ViewRay, Inc. (OTCQB: VRAY) at the LD Micro “Main Event” 2015 in Bel Air, CA.

In this video interview, Mr. Raanes and our host discuss the following topics: Overview of ViewRay, Inc., Describes the company’s medical device, MRIdian®, Where the technology comes from and currently treating patients, Explains the process for approval process, and where they have been approved, Discusses various indications for the company’s device, Reimbursement, Mr. Raanes’ background, Growth drivers for ViewRay, Inc.

December 15, 2015

Groundbreaking Therapy Opens Window To See Cancerous Tumors In Motion

With the first MRI-guided radiotherapy system in the western U.S.— and one of only three locations in the world — UCLA radiation oncologists have an unparalleled ability to see and accurately target cancerous tumors, while making real-time adjustments to treatment delivery. Beverly Hills Courier, November 2014

November 14, 2014

MRI-Guided Radiation Therapy

Precise adaptive radiation therapy guided by real-time MRI images could prove a significant advance in radiation oncology. Integrating those two tools is the driving force behind the MRIdian system, a combined real-time MRI and radiation therapy delivery process developed by Cleveland-based ViewRay. Radiology Today, September 2014, Vol. 15 No. 9 P. 20

September 1, 2014

Visualizing Tumors During Treatment

A new technology called MRI-guided radiation therapy allows tumors to be visualized in real-time during treatment. In what has been called “a world’s first,” physicians at Siteman Cancer Center at Barnes-Jewish Hospital and Washington University School of Medicine in St. Louis began treating patients with this new therapy in January 2014. Radiation Oncology News for Administrators, June 2014 This article was originally published in Volume 24 No 2 of "Radiation Oncology News for Administrators" © 2014 The Society for Radiation Oncology Administrators (www.sroa.org). The Society for Radiation Oncology Administrators, the authority for radiation oncology operations, provides education, advocacy and information to radiation oncology administrators.

June 1, 2014

ViewRay MRI-Guided Radiation Therapy Used to Treat Cancer Patients

The ViewRay system, a MRI-guided radiation therapy system, is being used to treat patients at Siteman Cancer Center at Barnes-Jewish Hospital and Washington University School of Medicine in St. Louis, Mo. The ViewRay system provides a combination of simultaneous radiation therapy delivery and continuous magnetic resonance imaging (MRI) for the treatment of cancer. Imaging Technology News, February 2014

February 10, 2014

Breaking News: World’s only MRI-guided RT System Treats First Patients

The Siteman Cancer Center at Barnes-Jewish Hospital and Washington University School of Medicine in St. Louis, Missouri has started to treat patients using the ViewRayTM system, the world’s first and only real-time MRI-guided radiation therapy system. The Advisory Board, February 2014

February 7, 2014

ViewRay system gives new insight on MRI-guided therapy for patients

Cancer patients are receiving a significant boost in their treatment options as ViewRay’s (Cleveland) MRI-guided radiation therapy system is being used to treat patients at Siteman Cancer Center at Barnes-Jewish Hospital and Washington University School of Medicine (St. Louis). Medical Device Daily, February 2014

February 1, 2014

Interlinked Motion Control Key to MRI-Guided System

The collimators in the MRI-guided radiotherapy system require multiple components to shape gamma ray radiation therapy beams, and each has to be precisely controlled by one interlinked motion control system. Medical Design, March 2013

March 11, 2013

A New View of Cancer Treatment

ViewRay's president believes the company's MRI machines will revolutionize radiation therapy. "I think this will change the way radiation oncology is practiced,” says Chris Raanes, ViewRay president and CEO. “Because once you've got the ability to see what you are doing in real time, how could you ever go back?” Crain's Cleveland Business, March 2013

March 4, 2013

ViewRay Receives FDA Clearance for MRI-Guided Radiation Therapy System

By using real-time MRI, the ViewRay system shows soft tissue as it is being treated and adjusts for its movement in real time, without using any additional radiation. medGadget, May 2012

May 31, 2012

ViewRay Secures Another $16 Million From Investors

ViewRay is well capitalized for its product launch, says CFO David Chandler, noting that the company has raised $45 million since 2010. Crain's Cleveland Business, March 2012

March 13, 2012

  Global Info

CUSTOMER LOGIN

Please log in to access the ViewRay Customer Portal. To request access, please click here. Request will be reviewed within 2 business days.

Existing Users Log In
   

This site uses cookies and other tracking technologies to assist with navigation and your ability to provide feedback, analyze your use of our products and services, assist with our promotional and marketing efforts, and provide content from third parties. Cookie Policy

Accept